WELAB BARCELONA

Scientific Services

At Welab Barcelona we have end-to-end technological capabilities, expertise, and in-depth knowledge of the key steps of the pharmaceutical R&D process and standards. We aim to be your partner in the Discovery and Development of new drugs or repurposing approaches for providing next generation therapies to patients.

Welab Barcelona platform offers drug discovery and development services along with know-how for supporting your drug R&D program, including gap identification, definition of the critical path, value proposition, and competitive differentiation.

WELAB BARCELONA

Drug discovery workflow

The research center has integrated capabilities spanning the entire drug discovery value chain, from target identification to pre-clinical development as well as clinical phase and regulatory support.

WELAB BARCELONA

Who we are

Welab Barcelona is  a singular initiative of the technological centre of excellence Leitat, a trademark of the non-profit private entity Acondicionamiento Tarrasense.

At our core, we are a dynamic and well-balanced team poised for excellence in the pharmaceutical industry. With an average of over 20 years of experience in the field, our board members bring a wealth of industry knowledge to the table.

Our team comprises a highly motivated group of scientists, ranging from early licensed professionals to senior collaborators. We foster a culture of innovation and dedication, driven by our passion for advancing pharmaceutical science.

WELAB BARCELONA

News

Get in touch

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS